THE INTELLIGENCE BRIEFING OF THE INNOVATION ECONOMY
DAILY · SUNDAY · MONTHLY
OPENING ESSAY
The Work That Remains
Capital can keep tomorrow possible. The remaining work decides what answers back.
Six moves place capital behind work that is still waiting to answer back: a game cohort, a rehabilitation portfolio, a clinical record, an orbital factory, a concentrated fund, and a multi-silicon cloud.
When the work does not answer back, hope becomes the decision to leave tomorrow open.
Some days, the work does not answer back. You give it another hour, another decision, another piece of yourself, and the room stays quiet. There is no new signal to tell you the effort is working. The personal pressure does not wait outside the door while you build. It comes in with the anxiety, the fatigue, and the private question of whether you have placed too much of your life on a future that still has not introduced itself.
People make perseverance sound heroic because they usually tell the story after it worked. From the middle, it can feel far less elegant. It is a person looking at a problem that has outgrown the plan, trying to find enough steadiness to make one more decision when there is no safety net beneath it.
That is the stretch where inspiration becomes unreliable. The thing you are building may be too large to carry in your head that day, so the work has to become smaller and more honest. One call that cannot wait. One correction. One page. One customer problem that deserves a real answer. One piece of the foundation that will still be there tomorrow. You do not need to put on confidence for the room. You need to leave the door open for the work to answer back.
Hope gets described like a feeling. At the hard end of building, it is closer to an operating decision. It is choosing to leave room for evidence you do not have yet. It is refusing to let a difficult week become the final verdict on an idea, a company, or yourself. It does not make the pressure lighter. It gives the pressure somewhere to go besides the exit.
Founders are often celebrated for belief after the record gives everyone permission to call it vision. The difficult days arrive before that permission, when belief feels private and progress is too small to explain. There are no clean answers for those days. There is only the obligation to be honest about what hurts, protect what can be protected, and do the next piece of work that keeps tomorrow possible.
Much of the innovation economy is built in that unphotographed space. Before the announcement, before the customer proof, before anyone calls the founder resilient, somebody has to remain present with an unfinished thing. A future does not have to be visible yet to need someone who will stay long enough to meet it.
Here's to Chris McGill and Jose Avila (Burlingame Studios); Todd Cushman (Bioness Medical); Nikolaj Hendriksen and Mark Rosenvinge (Hi Rasmus); Shishir Bankapur (Helogen); Omri Casspi and Ori Striechman (Swish Ventures); and Zain Asgar, Michelle Nguyen, Omid Azizi, Natalie Serrino, and James Bartlett (Gimlet Labs). Keep pushing forward.
Capital Opens Tomorrow. The Work Still Has to Meet It.
Capital can keep tomorrow possible. It cannot finish the work waiting there. Today's record moves from a mobile game cohort and a rehabilitation portfolio into autism-care infrastructure, orbital manufacturing, concentrated venture ownership, and the physical limits of AI inference.
Three exact current company financings total $357.1M. Gimlet Labs accounts for $300M of that lane, followed by Hi Rasmus at $50M and Helogen at $7.1M. The concentration is the point: this is a large AI-infrastructure round beside two companies whose proof will be earned one clinical session and one orbital mission at a time.
The remaining structures carry different obligations. Burlingame Studios secured $12M in user-acquisition financing tied to the timing of game-cohort revenue. Bioness Medical has a $15M senior credit facility, with $10M funded at closing and up to $5M available later. Swish Ventures closed a $250M fund that it expects to concentrate across roughly 12 companies. None of those amounts belongs inside the exact-equity subtotal.
The opening essay makes hope an operating decision: protect what can be protected and do the next piece of work that keeps tomorrow possible. Burlingame has to keep acquisition economics intact after the ad bill is paid. Bioness has to carry devices through clinical, reimbursement, and patient handoffs. Hi Rasmus has to make cleaner documentation useful to both clinicians and institutions.
Helogen's next answer comes back from orbit as material, process data, and customer confidence. Swish has to make a concentrated portfolio feel supported rather than merely selective. Gimlet has to turn a new architecture into dependable capacity where software choices meet silicon, power, cooling, and contracts.
The announcement gives each team more room. The record becomes valuable after that room fills with customer decisions, clinical evidence, field results, manufacturing discipline, and the ordinary work that does not photograph well.
The announcement gives the work more time. Evidence decides what answers back.
Candid Health moves into oncology through Flatiron
Candid Health and Flatiron Health announced a partnership that will bring Candid's revenue-cycle platform to oncology practices across Flatiron's network. The work now moves into one of healthcare's more complicated billing environments, where treatment regimens, authorizations, claims, and collections have to stay connected.
WTMM first carried Candid Health with its $120M Series D. This partnership is what comes after the announcement: a previously funded company earning a path into a specialized operating system. It adds no new capital record.
M12 puts operating range beside the infrastructure check
M12 lists Peter Lenke as a managing partner leading investments across AI applications, developer tools, and enterprise opportunities after roles in Atlassian Ventures and corporate development. The team context matters today because M12 also participated in Gimlet Labs' Series B.
The personnel record adds no dollars to the issue. It shows how a corporate venture platform can pair capital with someone who has worked across investing, product-adjacent strategy, partnerships, and M&A while a portfolio company enters a much larger operating chapter.
Source-verified ecosystem signals. These items are not funding records or capital events and are excluded from every capital count and total.
WHAT THE WORK STILL REQUIRES
Each record appears once in WTMM's operating map.Editorial classification, not a score or causal model.
EXACT COMPANY-FINANCING CONCENTRATION
Share of the $357.1M exact company-financing laneTHEMES IN MOTION
NUMBERS THAT MATTER
CAPITAL FLOW
CAPITAL BEHIND TODAY'S MOVES
Burlingame Studios
A player can finish a garden in 10 minutes. The revenue curve attached to that session may take months to finish telling the truth.
That gap is where mobile gaming starts behaving like working capital. The studio pays an acquisition channel for attention now. The cohort returns its answer through retention, in-app purchases, and payback later.
Gamigion reports that Burlingame Studios has secured $12M in user-acquisition financing from PvX Partners, primarily to scale Flourish by Garden Joy, the newly renamed version of Garden Joy. Exact pricing, maturity, covenants, and draw terms were not disclosed in the public reporting.
PvX describes its model as non-dilutive capital underwritten against cohort performance. The structure gives studios a way to finance marketing without selling another piece of the company every time a live game finds room to grow.
Chris McGill, co-founder and CEO, and Jose Avila, co-founder and CTO, are not learning casual games from a slide deck. Burlingame's founding team came through CrowdStar and Glu Mobile, with experience around Design Home and Covet Fashion before building a studio aimed at people who may not even describe themselves as gamers.
Flourish fits that thesis. It turns gardens, patios, furniture, plants, and daily design challenges into a live creative loop. Google Play shows more than 1M downloads, roughly 45K reviews, and a 4.7 rating. The game also features Better Homes & Gardens-branded challenges.
Scopely invested $20M in Burlingame Studios in March 2022. That earlier investment and this $12M facility belong in the same company history, but they should not be added together as if the capital works the same way. One helped launch a studio. The other is being pointed at the expensive interval between finding a player and collecting the revenue that player may eventually produce.
User acquisition is often discussed like a marketing tactic, but at live-game scale it becomes a financing decision. A promising cohort can be profitable on paper while the studio still lacks enough cash to keep buying the next one.
For operators, that makes growth a cash-management problem.
PvX is betting its underwriting can read that timing well enough to fund the gap. Burlingame Studios is betting Flourish can absorb more distribution without losing the economics that made the facility possible.
The garden may be designed one challenge at a time. The business now has $12M riding on whether the next cohort keeps growing after the first ad bill is already paid.
Bioness Medical
A patient does not recover inside one product category. The clinic still has to connect muscle activation, gait training, balance work, evidence, reimbursement, and a device the patient can actually use at home.
That is the operating reality behind Bioness Medical's new $15M senior credit facility from Horizon Technology Finance. Horizon funded $10M at closing and left up to $5M available for future growth. This is credit capacity rather than a $15M equity round, and the distinction matters.
Bioness has spent more than 20 years in neurorehabilitation. Its portfolio spans functional electrical stimulation, robotic gait support, interactive therapy, and, after an April acquisition, the PoNS neuromodulation system.
Accelmed acquired the business from Bioventus at the end of 2024 and re-established Bioness as an independent company. Since then, each product has brought more work around clearance, clinical integration, training, payer access, and patient adoption.
FDA records show a May 13 PoNS clearance for chronic stroke-related gait deficits when the prescription device is used alongside supervised therapeutic exercise in adults 22 and older. The clearance opens one door while Bioness still builds the evidence, reimbursement, clinician confidence, and commercial system that can get a patient through it.
Todd Cushman, co-founder and CEO, says the facility adds flexibility for innovation, portfolio expansion, and global service. Horizon's CIO Paul Seitz points to Bioness's proven model and market position. That is lender language, but the transaction puts senior capital behind a commercial medical-device business.
$10M is funded, and another $5M is available. Interest rate, maturity, covenants, warrants, and draw conditions were not disclosed. That leaves an incomplete capital picture, exactly the detail operators should keep straight when debt gets dressed like a funding round.
The strongest use of this money may be less photogenic than another product reveal. Bioness has to make several rehabilitation modalities work as one clinical and commercial story without letting portfolio breadth outrun evidence or access. The hard handoffs run from regulator to clinic, clinic to payer, therapist to patient, and device to daily life.
In neurorehabilitation, value appears when technology survives every handoff between the company and the person trying to move again. Bioness has $10M more to carry that work today, with another $5M waiting behind terms it has not disclosed.
Hi Rasmus
The clinical record inside an autism-care session has to satisfy two audiences at once. It must help the clinician understand the child in front of them, then survive the supervisor, payer, and audit process that arrives later.
Hi Rasmus built its business inside that tension. Founder and CEO Nikolaj Hendriksen started the company after navigating autism care for his son, Rasmus. The platform brings data collection, treatment planning, documentation, scheduling, outcomes reporting, and AI-supported tools into one ABA-first clinical system.
Updata Partners VIII has invested $50M through a strategic minority investment. Hi Rasmus says it reached this point without outside capital while growing to serve more than 1,000 organizations across all 50 U.S. states and 90 countries. It also reports supporting more than 19.6M hours of client sessions annually and onboarding two of the world's largest ABA providers.
Updata General Partner Braden Snyder will join the board. The firm describes a rapidly growing, profitable company with strong retention and unit economics, although the supporting financial detail was not disclosed.
Hi Rasmus plans to invest in product, AI, enterprise capabilities, integrations, outcomes research, infrastructure, and go-to-market scale. CTO Mark Rosenvinge and the product organization now have more room to connect work usually split across clinical systems and billing-first software.
CMS released an ABA oversight toolkit in August after reporting that program spending rose much faster than the number of children receiving services from 2021 through 2025. That scrutiny does not belong to Hi Rasmus. The operating demand behind it does: individualized care, credible documentation, and evidence that the system produces the outcomes it claims.
Taking a minority investment after bootstrapping puts a growth investor on the board while founders retain majority ownership. Hi Rasmus gets capacity without handing away the product mission.
The next stretch will be decided inside ordinary sessions. If clinicians can collect cleaner data, finish documentation with less friction, and give supervisors a clearer view of outcomes, the platform can scale because care teams get time back. If the software becomes another administrative layer, $50M only buys a larger version of the same problem.
Hi Rasmus now has the capital to make clinical work and institutional proof meet in the same record. That handoff will keep happening one child, one clinician, and one session at a time.
Helogen
A surgeon will never buy microgravity. A surgeon will buy a material that arrives with evidence, sterility, traceability, and a reason to trust what happens after it enters the body.
That gap is where Helogen is placing a factory.
The New York and Los Angeles company has raised a reported $7.1M Seed round co-led by RRE Ventures and Oceans, with One Way Ventures and Blisce participating. Helogen's own disclosure puts total funding at $7.9M. AUM, Aurelia Foundry, Mana VC, and angels appear in the broader investor base.
Founder and CEO Shishir Bankapur started the business in 2022 as Odyssey SpaceWorks. Helogen is now narrowing the idea of autonomous laboratories in orbit into a harder commercial job: manufacturing biomaterials that can return to Earth and enter regulated products.
HEL-IOS combines cultivation, fluid management, processing, harvest, imaging, and sequencing in a zero-crew orbital factory. Helogen wants to own enough of the process to explain what happened to the material from launch through recovery.
October brings the next proof. One mission is planned to produce Helogen's biopolymers for orthopedic scaffolds used in knee and shoulder repair. Another will manufacture protein material for LambdaVision's artificial retina, taking that partner beyond the International Space Station for the first time.
The science is interesting. The handoffs decide whether it becomes a business.
Microgravity may allow biological structures to form differently. A regulator still needs bioburden controls, process consistency, material recovery, and chain of custody. A customer still needs a dependable product. Orbit makes those obligations more expensive to inspect.
Helogen says these flights begin work toward GMP-oriented production and future FDA oversight. That is a path, not an approval. It has outlined 8 missions over the following year, mixing proprietary products with customer-funded research.
RRE Ventures General Partner and COO Will Porteous called Helogen's vision the most complete approach to scaling biomanufacturing in space that his firm has seen. The company is trying to own the industrial loop, from biology and hardware to spacecraft and orbital infrastructure.
Now the loop has to close on Earth. Each flight must return more than an impressive mission patch. It must return usable material, better process knowledge, a cleaner regulatory record, and enough customer confidence to book the next factory run.
Swish Ventures
Twelve companies. Roughly $20M apiece. Swish Ventures just made concentration expensive.
Swish Ventures completed a $250M raise for Swish III, its new Seed and Series A fund. The vehicle lifts reported AUM to about $800M. Sequoia Capital, U.S. pension funds, endowments, and other institutional and family-office backers supported it.
That headline is large. The portfolio plan is deliberately small.
Omri Casspi and Ori Striechman expect to invest in roughly 12 companies across cybersecurity, AI and advanced infrastructure, Physical AI, defense, industrial AI, and technology for governments. At an average of about $20M per company, every yes carries weight.
Concentration is easy to admire from a distance. Up close, it means fewer places to hide a weak decision and more time owed to every founder at the table. The capital has to show up in recruiting, customers, later rounds, and the quiet weeks after the announcement.
Swish has earned the right to make the wager bigger. Forbes reports 20 portfolio companies, with eight now valued above $1B. Cognition, Eon, Upwind, and Applied Compute sit inside the same AI, cloud, and security demand that shaped the firm's early thesis.
Those marks are evidence of access and selection, not realized returns. The reported $800M AUM should not be confused with the $250M raised for this vehicle. Private valuations move, and distributions are different from headlines.
The architecture around Swish III reaches beyond one fund. Casspi began with the $36M Sheva vehicle in 2022, launched a $63M Swish fund in 2024, and added a $100M Opportunity Fund in late 2025. Swish can now enter earlier and keep supporting selected companies as they grow.
That can be powerful for founders who want a partner with room to stay involved. It also makes the selection funnel brutally narrow. A 12-company plan is a promise that attention will compound alongside ownership, not disappear into a portfolio dashboard.
Institutional LPs are backing that promise. Sequoia is the only investor named publicly, while the pension funds, endowments, and family offices remain undisclosed. Their bet is that Casspi's founder access and competitive judgment can become an institution without turning into an assembly line.
The next proof will live inside the work around those 12 companies: which founders get chosen, how much ownership Swish earns, and whether a larger pool still leaves room for the calls and decisions that made concentration valuable in the first place.
Gimlet Labs
One inference request can look simple from the application layer. Underneath it, an infrastructure team is deciding which chip handles each phase and whether power, memory, cooling, and latency can keep the agent useful.
Gimlet Labs is raising infrastructure-scale money to make that machinery disappear from the developer's view.
The San Francisco company announced a $300M Series B led by Andreessen Horowitz at a $3B valuation, bringing total funding to $392M. Sapphire Ventures, Menlo Ventures, Arm, M12, Eclipse, Factory, Tiger Global, and a broad group of new and returning investors joined the round.
Gimlet emerged from stealth in October 2025 with a $12M Seed, then raised an $80M Series A in March. 5 months later, the question is how quickly it can operate heterogeneous inference at datacenter scale.
Zain Asgar, Co-Founder and CEO, built Gimlet with Michelle Nguyen, Omid Azizi, Natalie Serrino, and James Bartlett. The team previously built distributed systems at Pixie Labs before New Relic acquired it.
Gimlet breaks an AI workload into pieces and maps each to the hardware that fits it best. GPUs can keep compute-heavy work while memory-bound phases move elsewhere. A compiler, runtime, and orchestration layer keep the mixed fleet behaving like one system.
The pitch sounds elegant because the operational problem is not. Mixed systems bring different performance profiles, networking demands, rack densities, power needs, and cooling requirements. Sometimes the advantage lives in a compiler. Sometimes it is sitting in a pipe, waiting for an engineer.
Gimlet says it has added billions in contracted revenue since March, built a gigawatt-scale pipeline, and is scaling toward hundreds of megawatts of managed capacity. It also reports 5-10X speedups for the same power footprint. Those are company-reported figures, not independent benchmarks.
The capital will expand Gimlet's team and cloud operations. Andreessen Horowitz is backing a shift in where AI infrastructure value may collect: making a mixed fleet feel boring enough for a developer to trust.
Performance can win the demo. The business is built when the system keeps choosing the right hardware across changing workloads and physical constraints without handing the complexity back to the customer. Gimlet now has the money to carry that promise into facilities where software decisions meet megawatts, cooling loops, and contracts.
THE CLOSING SIGNAL
Capital can keep tomorrow possible. It cannot do tomorrow's work.
The next answer will not arrive from the headline. It will come from retention, reimbursement, clinical practice, recovered material, founder support, and infrastructure that holds under load. Each company and fund now has more room to stay with the unfinished thing. What remains is the work that makes the future visible.
FREE PUBLICATION · EVERY EDITION
Every issue. Delivered when it publishes.
WTMM is currently free. Subscribe once and receive every Daily, Sunday, Monthly, and future edition automatically.NO CARD REQUIRED